Skip to Main Content
Welcome to the Scientist.com Marketplace

Go to Main Navigation

10-046

Tofacitinib

ProSci

DESCRIPTION

Potent cell permeable JAK3 inhibitor (IC50 = 1nM). Shows also JAK-1 inhibitory activity. Immunosuppressive and anti-inflammatory agent. Inhibits signaling through heterodimeric receptors associated with JAK3, JAK1, or both of them, with functional selectivity over JAK2-paired receptors. Blocks downstream STAT signaling, resulting in potent inhibition of several cytokines, including interleukins 2, 4, 7, 9, 15 and 21, which are integral to lymphocyte activation, function and proliferation. Investigated for several autoimmune disorders including, rheumatoid arthritis and psoriasis. Potent and selective inhibitor of HIV-1 replication and virus reactivation in vitro. It is investigated against the spread of the SARS-CoV-2 (COVID-19). PRK1 inhibitor.

DETAILS

  • Cas: 477600-75-2
  • Purity: greater than or equal to 98%
  • Smiles: [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N
  • Formula: C16H20N6O
  • Storage: Short Term Storage: +4C. Long Term Storage: -20C. Handling Advice: Keep cool and dry. Protect from moisture and oxygen. Use/Stability: Stable for at least 2 years after receipt when stored at -20C.
  • Shipping: Room Temp
  • Inchi Key: UJLAWZDWDVHWOW-YPMHNXCESA-N
  • Solubility: Soluble in DMSO (20mg/ml) or DMF (5mg/ml). Slightly soluble in ethanol or water.
  • Physical State: Lyophilized
  • Additional Names: CP-690550; Xeljanz; Tasocitinib
  • Predicted Molecular Weight: 312.4